Discovery & Development

What biosecurity risks do exo-microorganisms pose?

Ross Burn presents the story behind his career, including setting up a company on process chemistry and his views on industry 4.0.

Implementing green practices in clinical trials.

Oligonucleotide-based therapeutics present manufacturers with specific processing and characterization challenges.

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.

Novo Nordisk's Stephen Gough explains how pharma can address the cardiovascular risks associated with type 2 diabetes.

How can we effectively manage the treatment of type 1 diabetes?

How can companies avoid the risks of HPAPI containment and handling?

Can machine learning offer mass spectrometry a boost for drug discovery?

Fujifilm Toyama's influenza treatment passes COVID-19 trial.